FDA Approved: EOVIST — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)

View source ↗

Summary

FDA notes Bayer's supplemental application for EOVIST (gadoxetate disodium) to modify the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• EOVIST (GADOXETATE DISODIUM)

Snippet

SUPPL AP for EOVIST (GADOXETATE DISODIUM)